Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Ruxolitinib Combined With Dexamethasone for Pediatric Refractory and Secondary Hemophagocytic Lymphohistiocytosis

NCT03795909 is registered in ClinicalTrials.gov with Capital Research Institute of Pediatrics as lead sponsor.

NCT NCT03795909
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03795909 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Ruxolitinib Combined With Dexamethasone for Pediatric Refractory and Secondary Hemophagocytic Lymphohistiocytosis
Lead sponsor
Capital Research Institute of Pediatrics
Phase
Phase 1/2
Overall status
Unknown status
Start date
March 1, 2017
Completion date
March 1, 2022
Enrollment
50 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hemophagocytic lymphohistiocytosis